Last reviewed · How we verify
Alpha Interferon
Alpha Interferon works by stimulating the body's immune system to fight viral infections and cancer.
Alpha Interferon works by stimulating the body's immune system to fight viral infections and cancer. Used for Chronic Hepatitis C, Multiple Sclerosis, Hairy Cell Leukemia.
At a glance
| Generic name | Alpha Interferon |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | Interferon |
| Modality | Small molecule |
| Therapeutic area | Oncology, Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Alpha Interferon is a type of cytokine that activates immune cells, such as natural killer cells and T cells, to recognize and destroy infected cells or tumor cells. This leads to the production of other cytokines and the activation of various immune responses.
Approved indications
- Chronic Hepatitis C
- Multiple Sclerosis
- Hairy Cell Leukemia
- Kaposi's Sarcoma
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Depression
- Anxiety
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Rash
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (PHASE3)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (PHASE1, PHASE2)
- Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (PHASE3)
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |